Management Of Biologic Agents During Pregnancy In Patients With Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) affects women in their peak reproductive years. Since disease activity has been shown to increase the risk of pregnancy and neonatal complications, it is generally advised that women continue appropriate medical therapy throughout pregnancy. There is growing evidence that the use of biologics is safe during pregnancy and does not increase the incidence of congenital malformations. However, recent studies confirming the placental transfer of anti-tumor necrosis factor (TNF)-alpha antibodies and the potential impact of these agents on the development of the neonatal immune system are concerning. Results from prospective trials with long-term follow-up will provide further insight into the impact of these drugs on neonatal health and help clarify the proper use of these agents during pregnancy.